List of Excipients in Branded Drug DICLOFENAC POTASSIUM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Leading Pharma LLC	DICLOFENAC POTASSIUM	diclofenac potassium	69315-275	GELATIN
Leading Pharma LLC	DICLOFENAC POTASSIUM	diclofenac potassium	69315-275	GLYCERIN
Leading Pharma LLC	DICLOFENAC POTASSIUM	diclofenac potassium	69315-275	HYDROCHLORIC ACID

Generic Drugs Containing DICLOFENAC POTASSIUM

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA, Inc.	diclofenac potassium	0093-0948	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA, Inc.	diclofenac potassium	0093-0948	FD&C BLUE NO. 2
Teva Pharmaceuticals USA, Inc.	diclofenac potassium	0093-0948	FD&C RED NO. 40

What are the Most Frequently-Used Excipients in DICLOFENAC POTASSIUM?

# Of NDCs	Excipient
29	ANHYDROUS LACTOSE
2	ASPARTAME
62	CELLULOSE, MICROCRYSTALLINE

Excipient Strategy and Commercial Opportunities for Diclofenac Potassium

Last updated: February 27, 2026

What excipients are used in diclofenac potassium formulations?

Diclofenac potassium formulations typically include excipients that optimize drug stability, absorption, and patient compliance. Common excipients incorporate:

• Binders: Microcrystalline cellulose maintains tablet integrity.
• Disintegrants: Croscarmellose sodium accelerates disintegration.
• Diluents: Lactose monohydrate or cornstarch enhance bulk.
• Lubricants: Magnesium stearate ensures smooth manufacturing.
• Coatings: Hypromellose or film coatings improve swallowability and stability.

Extended-release formulations often employ osmotic agents or asymmetric coatings, such as ethylcellulose or sodium alginate, to modulate drug release.

How does excipient strategy influence market positioning?

A well-designed excipient profile impacts:

• Bioavailability: Excipients aiding rapid disintegration, like croscarmellose sodium, improve onset of action.
• Stability: Protective coatings prevent hydrolytic degradation.
• Patient compliance: Tastes-masking agents or novel delivery forms reduce GI discomfort.
• Manufacturability: Excipients that enable high-speed production reduce costs.

Innovations in excipient technology can enable extended-release or multi-particulate formulations, opening avenues for differentiated products.

What commercial opportunities exist through excipient innovations?

Market expansion is driven by:

• Advanced formulations: Controlled-release tablets or transdermal patches increase therapeutic adherence.
• New excipient use: Incorporating solubilizers like cyclodextrins enhances bioavailability for low-soluble salts.
• Personalized medication: Use of biocompatible, biodegradable excipients supports patient-specific formulations.
• Regulatory differentiation: Novel excipients with proven safety profiles facilitate regulatory approval of innovative products.

Research and development into excipients that improve stability, absorption, and patient experience provide avenues for premium pricing and market share gains.

How do regulatory considerations shape excipient choices?

Regulatory authorities require extensive safety data for new excipients. Established excipients with a history of safe use streamline approval processes. Patent protections often cover unique excipient combinations or novel controlled-release coating systems. Regulatory trends favor non-toxic, non-irritant excipients compatible across dosage forms.

What are the key challenges and strategies in excipient development?

Challenges include:

• Ensuring excipient compatibility with diclofenac potassium's chemical profile.
• Avoiding excipients that could cause adverse reactions or interfere with drug efficacy.
• Balancing cost with performance enhancements.

Strategies involve:

• Leveraging existing excipient repositories with proven safety.
• Developing proprietary excipient systems for extended-release or targeted delivery.
• Collaborating with excipient suppliers to tailor formulations.

Summary table of excipient uses in diclofenac potassium formulations:

Excipients	Function	Typical Use in Diclofenac K+ Formulations
Microcrystalline cellulose	Binder	Tablet integrity
Croscarmellose sodium	Disintegrant	Rapid tablet disintegration
Lactose monohydrate	Diluents	Bulk filler
Magnesium stearate	Lubricant	Manufacturing aid
Ethylcellulose	Coating for sustained release	Extended-release formulations

Key Market Trends

• Growing demand for non-steroidal anti-inflammatory drugs (NSAIDs) with improved safety profiles.
• Increasing adoption of controlled-release formulations to reduce dose frequency.
• Rising interest in innovative excipient systems that enhance absorption or enable transdermal delivery.
• Regulatory emphasis on excipient safety profiles to facilitate market approvals.

Key Takeaways

• Excipients in diclofenac potassium formulations focus on stability, absorption, and patient adherence.
• Innovations in excipient technology can enable differentiated products, including controlled-release and transdermal variants.
• Regulatory pathways favor well-characterized excipients, with opportunities for proprietary excipient combinations.
• Market growth relies on formulations that combine efficacy, safety, and patient convenience.

FAQs

1. What are the main challenges in developing excipient systems for diclofenac potassium?

Ensuring chemical compatibility, avoiding adverse reactions, and balancing cost with performance are primary challenges.

2. How can excipient innovations extend the market life of diclofenac potassium products?

By enabling new formulations such as extended-release or transdermal patches, excipient innovations can justify premium pricing and address unmet needs.

3. What regulatory considerations influence excipient selection?

Use of excipients with established safety profiles streamlines approval; novel excipients require comprehensive safety data.

4. What excipients are suitable for enhancing absorption in diclofenac potassium?

Cyclodextrins and solubilizers are common choices that improve solubility and bioavailability.

5. How does patient compliance influence excipient choice?

Use of taste-masking agents, non-irritant lubricants, and formulations reducing GI discomfort improve adherence.

---

References

[1] European Medicines Agency. (2021). Guideline on excipients in medicinal products for human use. EMA/CHMP/QWP/271074/2014.